Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues

被引:0
作者
Pallares, J
Rojo, F
Iriarte, J
Morote, J
Armadans, LI
De Torres, I
机构
[1] Hosp Arnau Vilanova, Dept Pathol & Mol Genet, Lleida 25198, Spain
[2] Hosp Gen Valle Hebron, Dept Pathol, Barcelona, Spain
[3] Hosp Gen Valle Hebron, Dept Urol, Barcelona, Spain
[4] Hosp Gen Valle Hebron, Dept Epidemiol, Barcelona, Spain
关键词
angiogenesis; VEGF; bFGF; Flt-1; FLK/KDR; PIN; prostate cancer;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Purpose: Vascular endothelial growth factor ( VEGF) is an angiogenic factor that stimulates endothelial cell growth and enhances vascular permeability. VEGF exerts its action by binding to the specific cell surface receptors, fms-like tyrosine kinase 1 (Flt-1) and fetal liver kinase 1 (FLK/KDR). In tumor angiogenesis, Vascular endothelial growth factor stimulates endothelial cells to produce Basic fibroblastic growth factor ( bFGF), which further enhances angiogenic activity. Very little information on the expression of VEGF, bFGF, and the receptors Flt-1 and FLK/KDR is available. Herein, we evaluate the expression of these angiogenic factors and receptors in normal prostate, high grade prostate intraepithelial neoplasia (HGPIN) and prostatic cancer (CaP). Materials and Methods: 58 selected surgical specimens exhibiting areas of normal prostate, HGPIN, and CaP were evaluated for microvessel density, and for VEGF, bFGF, Flt-1 and FLK/KDR protein expression by immunohistochemistry. Results were correlated with pathological data. Results: There was a statistically significant increase in the microvessel density and in the expression of the angiogenic factors VEGF, bFGF and the receptors FLK/KDR and Flt-1, in the premalignant and malignant tissues in comparison with normal prostatic glands. Microvessel density also correlated with higher Gleason grade, pathological stage and the expression of the receptors FLK/KDR and Flt-1. Conclusions: The "initiation switch" of angiogenesis was observed to be an early event consistent with the recruitment of new vasculature into high grade PIN lesions and it increased in the progression of prostatic cancer.
引用
收藏
页码:857 / 865
页数:9
相关论文
共 39 条
[21]   Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression [J].
Huss, WJ ;
Barrios, RJ ;
Foster, BA ;
Greenberg, NM .
PROSTATE, 2003, 54 (01) :8-16
[22]   Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia [J].
Jackson, MW ;
Bentel, JM ;
Tilley, WD .
JOURNAL OF UROLOGY, 1997, 157 (06) :2323-2328
[23]   Cancer statistics, 1999 [J].
Landis, SH ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 1999, 49 (01) :8-31
[24]   Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF [J].
Liu, B ;
Earl, HM ;
Baban, D ;
Shoaibi, M ;
Fabra, A ;
Kerr, DJ ;
Seymour, LW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 217 (03) :721-727
[25]   Vascular endothelial growth factor vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma [J].
Masood, R ;
Cai, J ;
Zheng, T ;
Smith, DL ;
Naidu, Y ;
Gill, PS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (03) :979-984
[26]  
Mazzucchelli R, 2000, PROSTATE, V45, P72
[27]   PROSTATIC INTRAEPITHELIAL NEOPLASIA - QUALITATIVE AND QUANTITATIVE-ANALYSES OF THE BLOOD CAPILLARY ARCHITECTURE ON THIN TISSUE-SECTIONS [J].
MONTIRONI, R ;
GALLUZZI, CM ;
DIAMANTI, L ;
TABORRO, R ;
SCARPELLI, M ;
PISANI, E .
PATHOLOGY RESEARCH AND PRACTICE, 1993, 189 (05) :542-548
[28]   EXPRESSION OF P160(ERBB-3) AND P185(ERBB-2) IN PROSTATIC INTRAEPITHELIAL NEOPLASIA AND PROSTATIC ADENOCARCINOMA [J].
MYERS, RB ;
SRIVASTAVA, SS ;
OELSCHLAGER, DK ;
GRIZZLE, WE .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (15) :1140-1145
[29]  
NAKAMOTO T, 1992, CANCER RES, V52, P571
[30]  
Rooman I, 1997, LAB INVEST, V76, P225